Our team work focuses on a group of key mitotic kinases both from a fundamental and a therapeutic point of view. Mostly, we have investigated the function and mechanism of action of the atypical Haspin kinase, a promising therapeutic target known for its role in cell division and its abnormally high expression in advanced-stage cancers.
Together with different medicinal chemistry, we developed specific heterocyclic inhibitors and degraders targeting Haspin. Using a combination of reverse genetics, chemobiology and chemogenetics approaches we identified a novel function of Haspin in autophagic regulation leading us to hypothesize that its overexpression in cancer cells may confer them a survival advantage.